Learn English: Regeneron Acquires 23andMe for $256 Million (hard)

Regeneron Pharmaceuticals, a biotechnology company, will purchase 23andMe for a total of $256 million.

This acquisition follows 23andMe's bankruptcy filing earlier this year, impacting millions of customers.

The deal includes substantially all of 23andMe's assets, ensuring continued DNA testing services.

Regeneron assures customers their privacy will be maintained, adhering to existing policies and regulations.